Cargando…

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Detalles Bibliográficos
Autores principales:	Zheng, Yawen, Lai, Qinghua, Zhao, Hanxi, Li, Xiaolin, Sun, Xiaorong, Xing, Ligang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626592/ https://www.ncbi.nlm.nih.gov/pubmed/34661984 http://dx.doi.org/10.1002/cac2.12227

Ejemplares similares

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
por: Moore, Margaret, et al.
Publicado: (2022)

DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
por: Hu, Mangze, et al.
Publicado: (2020)

Author Reply: In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
por: Balbach, Meridith L., et al.
Publicado: (2022)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer
por: Cathcart-Rake, Elizabeth, et al.
Publicado: (2014)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
por: Chen, Hanxiao, et al.
Publicado: (2022)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
por: Dai, Xin, et al.
Publicado: (2015)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients
por: Li, Feng, et al.
Publicado: (2021)

Integrated circulating tumor DNA and T cell repertoire predict radiotherapeutic response and outcome in non‐small cell lung cancer patients with brain metastasis
por: Peng, Ling, et al.
Publicado: (2023)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2021)

Genetic alternations and immune characteristics in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2021)

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Wang, Xiaowen, et al.
Publicado: (2021)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
por: Kepka, Lucyna, et al.
Publicado: (2021)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

KRAS Transitions and Villous Growth in Colorectal Adenomas
por: Risio, Mauro, et al.
Publicado: (2005)

Reply: Comment on ‘KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'
por: Renaud, Stéphane, et al.
Publicado: (2015)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer
por: Aldarouish, Mohanad, et al.
Publicado: (2019)

Smoking cessation before initiation of chemotherapy in metastatic non-small cell lung cancer: influence on prognosis
por: Linhas, Ana Rita Diegues, et al.
Publicado: (2018)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma
por: Reggiani, Francesca, et al.
Publicado: (2021)

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
por: Luo, Lian-Xiang, et al.
Publicado: (2017)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials
por: Chen, Wei, et al.
Publicado: (2022)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_634it1peh9ia9intdtr6crjmm8